June 7, 2022
June 7, 2022 – The U.S. FDA has approved an expanded indication for Sanofi’s Lantus® (insulin glargine) to improve glycemic control in adult and pediatric patients
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
June 6, 2022
June 6, 2022 – Amgen’s RiabniTM (rituximab-arrx), a biosimilar for Rituxan® (rituximab – Genentech and Biogen), is now FDA approved to for use with methotrexate
June 6, 2022
June 6, 2022 – GSK’s Priorix® (measles, mumps, and rubella vaccine, live) has gained FDA approval to provide active immunization for the prevention of measles
June 1, 2022
June 1, 2022 – TG Therapeutics is removing Ukoniq® (umbralisib) from the U.S. market due to a potential increase in the risk of patient death.
June 1, 2022
June 1, 2022 – The U.S. FDA has approved Beovu® (brolucizumab-dbll) 6mg, made by Novartis, to treat diabetic macular edema (DME). DME is a leading cause of blindness
May 31, 2022
May 31, 2022 – Evrysdi® (risdiplam) has received expanded approval to treat spinal muscular atrophy (SMA) in patients of all ages. It was previously indicated for
May 27, 2022
May 27, 2022 – Bristol Myers Squibb's Opdivo® (nivolumab) has received two new indications to treat esophageal squamous cell carcinoma (ESCC)
May 27, 2022
May 27, 2022 – Amneal Pharmaceuticals and Kashiv Biosciences have received FDA approval for Fylnetra® (pegfilgrastim-pbbk), a biosimilar of Amgen's Neulasta®